Probing infectious disease by single-cell RNA sequencing: Progresses and perspectives

Geyang Luo, Qian Gao, Shuye Zhang, Bo Yan

Abstract

The increasing application of single-cell RNA sequencing (scRNA-seq) technology in life science and biomedical research has significantly increased our understanding of the cellular heterogeneities in immunology, oncology and developmental biology. This review will summarize the development of various scRNA-seq technologies; primarily discussing the application of scRNA-seq on infectious diseases, and exploring the current development, challenges, and potential applications of scRNA-seq technology in the future.

Keywords:
- Single-cell RNA sequencing
- Infectious diseases

Contents

1. Introduction
2. The development of scRNA-seq technology
3. Applications of scRNA-seq in infectious disease
   3.1. Immune atlas study
   3.2. Study the host-pathogen interaction
   3.3. Studying immune repertoire
   3.4. Biomarker discovery for infectious diseases

Abbreviations:
- ACE2, Angiotensin-Converting Enzyme 2; ARDS, acute respiratory distress syndrome; ATAC-seq, Assay for Transposable-Accessible Chromatin using sequencing; BCR, B cell receptor; CEL-seq, Cell Expression by Linear amplification and Sequencing; CIU, clusterin; COVID-19, corona virus disease 2019; CRISPR, Clustered Regularly Interspaced Short Palindromic Repeats; Cytosq, gene expression cytometry; DENV, dengue virus; FACs, fluorescence-activated cell sorting; GNLY, granulysin; GO analysis, Gene Ontology analysis; HIV, Human Immunodeficiency Virus; IAV, Influenza A virus; IGLV/LJ/LC, Immune globulin light V/J/C region; IGHV/HD/HJ/HC, Immune globulin heavy V/D/J/C region; ILC, Innate Lymphoid Cell; LIGER, Linked Inference of Genomics Experimental Relationships; MAGIC, Markov Affinity-based Graph Imputation of Cells; MARS-seq, Massively parallel single-cell RNA sequencing; MATCHER, Manifold Alignment To CHaracterize Experimental Relationships; MCMV, mouse cytomegalovirus; mscRNA-seq, molecular crowding single-cell RNA barcoding and sequencing; MERFISH, Multiplexed, Error Robust Fluorescent In Situ Hybridization; MLV, Moloney Murine Leukemia Virus; MOFA, Multi-omics Factor Analysis; MOI, multiplicity of infection; PBMCs, peripheral blood mononuclear cells; pSca, plasmacytoid dendritic cells; PLAC8, placenta-associated 8; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SAVER, Single-cell Analysis Via Expression Recovery; sci-RNA-seq, single-cell combinatorial indexing RNA sequencing; seqFISH, single cell RNA sequencing technology; smart-seq, switching mechanism at 5′ end of the RNA transcript sequencing; SPLit-seq, split pool ligation-based tranome sequencing; STARTRAC, Single T-cell Analysis by RNA sequencing and TCR TRACKing; STRT-seq, Single-cell Tagged Reverse Transcription sequencing; t-SNE, t-Distributed stochastic neighbor embedding; TCR, T cell receptor; TSFP, thymic stromal lymphopoietin; UMAP, Uniform Manifold Approximation and Projection; UMI, Unique Molecular Identifier; 3C, Chromosome Conformation Capture.

E-mail addresses: zhangshuye@shphc.org.cn (S. Zhang), bo.yan@shphc.org.cn (B. Yan).
1. Introduction

Single-cell studies have greatly expanded our knowledge of cell subsets diversity and individual cell heterogeneity in organisms. The primary applications of these studies include single-cell analysis of transcriptome [1], DNA methylation [2], chromatin accessibility [3], chromatin interactions [4], histone modifications [5], histone marks [6], spatial transcriptome [7] and more. This review mainly focuses on scRNA-seq characterizing single-cell transcriptomes.

scRNA-seq technologies have greatly improved during the last decade and are widely used in immunology, tumor biology, developmental biology and other fields. Commercial scRNA-seq platforms, such as the 10X Genomics and BD Rhapsody, have automated single cell lysis, RNA extraction, cDNA reverse transcription and library construction [8–10]. These advancements in simplifying the methodology and improving the cost-efficiency have allowed scRNA-seq to become one of the most popular and powerful life science and biomedical research tools available [11,12].

2. The development of scRNA-seq technology

Tang et al. developed the first scRNA-seq method in 2009 [13,14]. In 2011, Islam et al. furthered the technology by applying barcode labeling and developing single-cell tagged reverse transcription sequencing (STRT-Seq) which made high-throughput scRNA-seq possible [15]. Subsequently, with the continuous improvement in cell separation and nucleic acid amplification processes, novel scRNA-seq technologies surged (Fig. 1). These new advances included plate-based linear amplification and sequencing (CEL-seq) [16], combinatorial indexing-based single-cell combinatorial indexing RNA sequencing (sci-RNA-seq) [17], microdroplets-based inDrop [18], and Drop-seq [19].

Before the rise of high-throughput technologies, plate-based methods were the mainstream scRNA-seq platforms, which includes CEL-seq, CEL-seq2, Massively parallel single-cell RNA sequencing (MARS-seq) and MARS-seq2 [12,20]. The emergence of unique molecular identifier (UMI) improved the quantification of mRNA contents by using random code for labelling individual mRNA strands [21]. Using UMI allows the investigator to distinguish the original template from the amplified sequence derived from the cDNA or library amplification [11,21]. UMI counting has been incorporated in many scRNA-seq methods, including CEL-seq, CEL-seq2, MARS-seq, MARS-seq2, Drop-seq, inDrop, etc. [11,22–25].

CEL-seq is based on linear amplification and uses a unique barcode primer to obtain reverse-transcription in a single tube, which decreases sequencing errors [16]. CEL-seq2, the improved version of CEL-seq, is based on microfluidic chips on Fluidigm’s C1 platform, giving it higher sensitivity, lower costs and less labor [26]. MARS-seq was previously the main large-scale method for scRNA-seq in immune profiling [27]. It uses fluorescence-activated cell sorting (FACS) of single cells into multi-well plates and subsequent automated processing, which leads to a significant increase in throughput and reproducibility [28]. MARS-seq2 was developed for index FACS sorting (recording the levels of surface marker for each sorted single cell) and based on the MARS-seq approach. The combination of FACS and scRNA-seq technology ensures MARS-seq2 can record both single-cell surface markers and transcriptomes, which is particularly useful for characterizing rare cell populations [20].

Other revolutionary platforms have emerged since 2015, such as Drop-seq and inDrop [18,19]. Drop-seq uses UMI and barcodes to mark mRNA from individual cells, which then facilitates pooled sequencing from multiple cells. However, this technique can only detect a limited number of genes (5000 at best) per cell. Currently, Drop-seq is more popular as it is a high-throughput platform for discovering new cell types, construction of cell differentiation trajectory, molecular mapping of differentiation process, embryonic development and more. [29–32].

Another commonly used scRNA-seq methods is Smart-seq2 [11,22], which enables detecting higher number of genes, about...
9000 per cell [11]. Although the number of cells assayed in each experiment is fewer, it is useful when dealing with samples containing limited cell numbers for traditional RNA sequencing, such as circulating tumor cells, early embryonic cells and some laboratory unculturable microorganisms [33]. Smart-seq2 also avoids the 3’ bias for most sequencing methods [11]. It uses MLV (Moloney Murine Leukemia Virus) reverse transcriptase which prefers to choose full-length cDNAs as substrates for its terminal transferase activity [34]. Special primer design also ensure identical primers for cDNA synthesis, which helps keep the PCR amplification efficiency consistent [34]. The combination of attributes listed above ensures the synthesis of full-length cDNA with the Smart-seq2. All exons of each transcript can be detected by Smart-seq2, which endues Smart-seq2 with the capability to detect alternative splicing [34,35]. The Smart-seq3 has recently emerged as an upgraded version of Smart-seq2 with 5’ UMI for even more effective sequencing [36].

Due to a significant reduction in sequencing costs, the number of cells detected by scRNA-seq has increased from 10^6 to 10^8 per assay, and continues to grow. Downstream bioinformatic analytical tools have also been rapidly developing such as dimensionality reduction and its visualization techniques. These include t-SNE (t-Distributed stochastic neighbor embedding) and UMAP (uniform manifold approximation and projection) [37]. Personalized analysis tools included pseudotime, gene ontology (GO) analysis and STRING database network analysis and others. With the improvement of scRNA-seq technology and cost-efficiency at such a rapid pace, the ability to assess the cellular heterogeneity in life science and biomedical research by scRNA-seq will only increase with time. In the next section, the application of scRNA-seq in infectious disease studies will be discussed, using examples of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), human immunodeficiency virus (HIV), cytomegalovirus, dengue virus (DENV), flavivirus, Mycobacterium tuberculosis, Trypanosoma brucei, Salmonella, Toxoplasma gondii and helminth.

### 3. Applications of scRNA-seq in infectious disease

#### 3.1. Immune atlas study

##### 3.1.1. Identifying novel immune cell subtypes

When facing various infectious pathogens, heterogeneous immune cells are involved in various important biological processes, such as pathogen recognition, killing and antigen-presentation. For example, macrophages can be divided into various tissue-resident subtypes whose transcriptomes are significantly different. The identification of novel immune cell subgroups and understanding of their molecular characteristics, kinetics and functions during the infection process will greatly facilitate our understanding of both infectious disease mechanisms and the development of subsequent treatment strategies. To illustrate our point, based on bulk transcriptome analysis, it was determined that helminth infection induced Trpm5^+ tuft cells expressed both neuronal and inflammation-related genes [38]. However, tuft cells could be subdivided into two subsets, tuft-1 and tuft-2, by scRNA-seq. Tuft-1 cells were mainly related to neuronal development, while tuft-2 cells primarily express thymic stromal lymphopoietin (TSLP) and other inflammation-related genes [39] (Fig. 2A). Using scRNA-seq and T cell receptor (TCR) clonal analysis, Waickman et al. report that clonal expanded T cells have unique transcriptional characteristics. A group of memory-precursor CD8^+ T cells expressing CD38 molecules was defined in this study [40]. Similarly, it was demonstrated that CD4^+ T cells latently infected with HIV could differentiate into two very different cell subtypes. The transcriptional level of HIV virus and the number of genes transcribed in type 1 cells were lower than those in type 2 cells, and type 1 cells were more difficult to be activated [41].

Macrophage subtypes have been identified in TB patients via scRNA-seq [42]. By utilizing the high-throughput and low-cost scRNA-seq technique called Seq-Well, Gierahn et al. identified three pulmonary macrophage subsets from TB patients. All these macrophages preserved the feature of TLR7/8 pathway activation,

---

![Fig. 2. Immune atlas study. (A) Identifying novel immune cell subtypes; (B) Detecting immune cell landscape during infection; (C) Detecting changes of inflammatory responses; (D) Identifying immune signaling pathways for differentially expressed genes during infection.](image-url)
which is involved in the intracellular recognition of *M. tb*. However, the levels of genes related to cell growth, cell metabolism and hypoxia varied in the different subtypes. The varying immunological status of pulmonary macrophages suggests that they have either distinct origins or adapted to different microenvironment in TB patients [42]. Notably, caution should be taken to interpret the reports of novel cell subtypes, considering the possible false positive, such as doublets. The examples described above clearly demonstrate that scRNA-seq can greatly facilitate the identification of novel immune cell subtypes during infection.

3.1.2. Profiling immune cell landscape during infection

The immune cells initiate host defenses against pathogenic infection. Profiling immune cell landscape characterize the overall immune cell compositions between physiological and infection conditions, which provides key information for understanding the pathogenic mechanism of infectious diseases. For instance, scRNA-seq analysis has divided the peripheral blood mononuclear cells (PBMCs) from HIV-1 envelope vaccinated neonatal and adult monkeys into 4 groups: B, T, NK, and monocyte [43]. It further demonstrated that each of the 4 cell clusters showed different patterns between neonatal and adult monkeys (Fig. 2B) [43]. A significant increase in the ratio of activated B cells was found in neonatal monkeys, indicating that the neonatal immune system produces a stronger protective response than that of adult monkeys during HIV infection [43]. This result also suggest that the expansion of activated B cells demonstrate that scRNA-seq can greatly facilitate the identification of novel immune cell subtypes during infection.

3.1.4. Identifying immune signaling pathways for differentially expressed genes during infection

scRNA-seq can not only identify the transcriptomic differences, but also map the cellular interacting networks. For instance, in one study aiming to understand B cell immunity against an influenza vaccine using scRNA-seq, it has been shown that a fraction of peripheral memory B cells were activated the vaccination, while other memory B cells remained inactive [51]. Expression differences in 172 genes have been found between activated and inactivated memory B cells, revealing the signaling pathways relevant to the host defense against influenza virus [51]. In another COVID-19 study, Wang’s group recently found the disease was associated with expression of multiple cytokines and the activation of inflammation-related signaling pathways in various activated cell subsets via scRNA-seq [52]. e.g., NK cells from healthy controls express genes related to antioxidant damage signaling pathways, while NK cells from COVID-19 patients show high expression of inflammation-related signaling pathways (Fig. 2) [52]. Similarly, using GO analysis of divergent genes, Zhang et al. showed that a subset of infected neutrophils was associated with pro-inflammatory response and neutrophil chemotaxis [49]. Thus, scRNA-seq enables the identification of immunological pathways that correspond to the differences in host gene expression throughout the course of an infection. This will deepen our understanding of the immunological processes occurring throughout the course of infection and assist the development of therapeutics for patients in different stages of infection.

3.2. Study the host-pathogen interaction

3.2.1. Identifying susceptible cell types

For a specific pathogen, the identification of susceptible cells is crucial for understanding the pathogenic mechanism. For example, using scRNA-seq and cluster analysis, Steuerman et al. identified 5 types of immune cells and 4 types of non-immune cells in sorted CD4+ and CD4- cells isolated from the lungs of both wild type and *Ifn-γ* knockout mice infected with *IAV* (Fig. 3). The first 3 days-post-infection (dpi), pro-inflammatory factors such as Tnf-α and Ccl3, were primarily produced by a special subset of PD-L1 + neutrophils. By 7 dpi, the virus is almost entirely cleared and chemokines including Ccl5 are primarily secreted by PMNs + macrophages [49]. In COVID-19 assessed by scRNA-seq, SARS-CoV-2 infection induced IL-1β and TNF-α production may promote mucin secretion from club cells, likely contributing to acute respiratory distress syndrome (ARDS) [50]. These studies showed that application of scRNA-seq technology can facilitate the studying of changes in inflammatory factors secretions over the course of infection, revealing important cellular and molecular pathogenic mechanism.
infected patients, inducing an altered cytotoxic response in CD8+ T cells. They also show that the virus primarily infects epithelial and macrophage subsets [62]. scRNA-seq can provide crucial information about cell types susceptible to infection which will help the development of strategies for intervention.

3.2.2. Studying infection dynamics

It is important to understand infection dynamics, which focus on how pathogen proliferate and disseminate in vivo and how these link to pathogenesis. These studies may facilitate the development of personalized therapies for patients at different courses of infection, which will enable hierarchical diagnosis/treatment and shortening treatment time. However, some of the obstacles in these studies are the heterogeneity issues, manifested in both host cells and microbial populations, which determines how the host and pathogen interact [63]. The dissemination of bacteria between different immune cells, pathogen recognition by those immune cells, and pathogen mediated immune cell death could be clarified using scRNA-seq. For example, Romas et al. analyzed the dynamics of the interaction between IAV and respiratory epithelial cells at the single cell resolution in the early stage of infection and found that the multiplicity of infection (MOI) of viruses infecting host cells had a great impact on host innate immunity [64]. High MOI leads to increase intracellular viral mRNA (Fig. 3B) and stronger antagonistic effects on innate immune responses, such as the suppression of IFN production [64]. It was also found that the early innate immune response caused by low dose virus infection had a protective effect on bystander cells, which could block the further spreading of the virus [64]. Similarly, Zanini et al. studied the dynamics of the interaction between flavivirus and host cells by virus-inclusive single cell RNA-seq, and identified several host factors specifically related to flavivirus infection, including proteins involved in endoplasmic translocon, signal peptide processing and membrane trafficking [65]. The dynamics of SARS-CoV-2 infection have also been addressed by scRNA-seq. Compared with patients with moderate and severe diseases, studies reveal great differences in the immune cell composition at early and late convalescent stages [52]. Therefore, scRNA-seq can discern the systematic effects of the interaction between pathogens and host cells, revealing varying effects caused by varying viral loads and stages of the host’s immune response.

3.3. Studying immune repertoire

Immune repertoire refers to all B cells and T cells with distinct antigen specificity at any given time. It has important applications in identifying potent neutralizing antibodies and testing the efficacy of vaccinations. B cell receptors (BCR) on the surface of B cells recognize and bind antigen. The BCR consists of two heavy chains (H chain) and two light chains (L chain). The H chain is composed of four parts: the variable region (V region), the diversity region (D region), the joining region (J region) and the constant region (C region). The L chain is composed of three parts: V, J and C region. Similarly, TCR on the surface of T cells is composed of TCR α and β chains with V, J and C region as well [66–68]. The diversity of the V region, along with different VDJ rearrangement, and the deletion or insertion of nucleotides at the junctions of different gene fragments create BCR and TCR diversity. The structure of the corresponding BCR gene, TCR, and coding gene are shown in Fig. 4. The immune repertoire analysis includes CDR3 sequence analysis, single cell VDJ statistics, TCR or BCR diversity analysis, and TCR or BCR sharing analysis between samples (Fig. 4E). scRNA-seq can accelerate the identification of neutralizing antibodies with potent therapeutic and prophylactic effects, which are vital for the prevention of the emerging or pandemic infectious diseases. For example, Xie’s group sequenced the antigen-enriched B cells from the plasma of convalescent patients with COVID-19 using scRNA-seq and BCR sequencing, and recovered 14 highly active virus neutralizing antibodies [69]. In vivo studies confirmed that one neutralizing antibodies, BD368-2, showed strong potential as a therapeutic [69]. scRNA-seq can also be applied to monitor the T cell responses after infection or test the efficacy of vaccination. Liao et al. recently performed the scRNA-seq and single cell TCR-seq on the bronchoalveolar lavage fluid from COVID-19 patients. They reported a greater...
increase of clonally expanded CD8$^+$ T cells in mildly infected patients than that of severely infected patients [70]. In another study, TAK-003 (a potential recombination tetravalent DENV vaccine) was found by scRNA-seq analysis of PBMC from patients post immunization and proven to be an excellent candidate eliciting the potent and durable T cell response [40]. Another group used single-cell BCR & TCR sequencing, revealing different types of T cell clonal expansion (Fig. 4F) and a unique composition of BCR immunoglobulin in convalescent COVID-19 patients [52]. Moreover, unique combinations of BCR genes is associated with specific pathogen infection. For instance, VDJ in severe COVID-19 patients had a different pattern when compared with health controls, indicating specific BCR-VDJ rearrangement in severe COVID-19 [48]. Thus, scRNA-seq, combined with BCR/TCR sequencing, could provide important insights into the adaptive immune responses against infection, and accelerate the development of neutralizing antibodies and specific vaccines. This is vital for the prevention of emerging or pandemical infectious diseases.

### 3.4. Biomarker discovery for infectious diseases

A biomarker refers to robust biochemical or cellular changes during certain biological process and has been widely applied in diseases diagnose and biomedical research [71]. Currently, concrete biomarkers for infectious diseases are limited, and further exploration is still required. scRNA-seq greatly facilitates the identification disease-related biomarkers. For example, Zanini et al. performed scRNA-seq on PBMCs from patients with dengue disease and found that the expression of MX2 in naive B cells and the expression of CD163 and IFITI in CD14$^+$CD16$^+$ monocytes were significantly up-regulated before severe dengue disease developed [72]. These upregulated genes may be used as biomarkers to predict the progress of dengue disease in the future [72]. Similarly, by comparing single cell transcriptomes of PBMCs between sepsis patients and healthy controls, Reyes et al. found that placenta-associated 8 (PLAC8) and clusterin (CLU) mRNA expression level in a monocyte subgroup called MS1 (monocyte states 1) were significantly higher in sepsis patients [73]. Another study refers to the discovery of biomarker for active TB. Cai et al. collected the PBMCs from healthy people, latent TB patients and active TB patients for scRNA-seq. They found that NK cell (CD3$^+$CD8$^+$GZMB$^+$) subsets were depleted in active TB patients, and this cell population recovered in cured TB patients, suggesting that this NK subset could be a marker to identify active TB patients and monitor treatment response [74]. These results were consistent with a multi-cohort research performed during tuberculosis infection [75], which reported that NK cell levels decreased in progression from latent infection to active TB, while NK cell number significantly increased at the end of treatment [75]. Hence, NK cell could be a novel biomarker for active TB. These studies indicate scRNA-seq can be applied to monitor gene expression patterns related to specific infections, which can reveal candidate biomarkers for disease diagnosis and prognosis.

### 4. Perspective

#### 4.1. The developmental trend of scRNA-seq

Since most of the information acquired by bulk RNA-seq can also be acquired by scRNA-seq, scRNA-seq shows great advantage in solving complex biological and clinical problems from a systematic approach. With the emergence of several commercial platforms, scRNA-seq is being increasingly utilized. The average cost of scRNA-seq has fallen to below $1 per cell [11,23], including the cost for library construction and sequencing, continuous improvement in cost-efficiency will encourage more application of scRNA-seq in developmental biology [76,77], oncology [78,79], neuroscience [31], etc. The combination of live cell sorting with scRNA-seq greatly improves sample viability, eliminating concern for most clinical tissue samples. Technical requirements for scRNA-seq data analysis are also decreasing, as the number of R language packages for scRNA-seq, such as Seurat and Monocle, and commercial data analysis platforms are growing rapidly. Researchers from Theis lab have summarized current mature practices for each step in scRNA-seq analysis [80], including linked inference of genomics experimental relationships (LIGER) (a tool to approximate the original data and to share factors across various datasets) [81] and Multi-omics factor analysis (MOFA) (a tool for analyzing matched data) [82]. Online servers could make the analysis of scRNA-seq data simpler and more comprehensive, such as alona and scQuery [83,84]. All these developments may gradually push the replacement of traditional bulk RNA-seq by scRNA-seq. However, in some special cases, bulk RNA-seq still has irreplacable advantages. For instance, certain types of cells are fragile during sample preparation, preventing them from being sequenced, whereas the bulk RNA-seq could handle it accurately. In addition, requirement of single-cell suspension plus high cell viability also prevent the application of scRNA-seq for most plant or special ani-
mal tissue samples. With recent development, bulk RNA-seq data can now be utilized to infer scRNA-seq data, such as SCRABLE algorithm [61,85–87]. Similar to bulk RNA-seq, microarray can detect the differential expression of RNA, but it depends on a hybridization generated signal. Although the sensitivity of gene expression score detected by microarray is reduced compared with bulk RNA-seq and scRNA-seq, microarray are still very popular in clinical research because of its simple use and fast results [88].

At present, mainstream commercial platforms for scRNA-seq include 10X Genomics and BD Rhapsody. The sample processing time of both platforms is within 30 min; and the entire process is integrated, including library construction, sequencing and data analysis (optional). In addition, the ratio of captured doublets by these two platforms is relatively low. While both are widely used in research fields such as immunology, oncology and neurology, there are still some minor differences between these two platforms. The sequencing throughput of 10X Genomics is higher than that of BD Rhapsody, and 10X Genomics has a unique technology that can complete spatial transcriptome sequencing [8,89]. More importantly, it’s easier to operate than the BD Rhapsody. On the other hand, the plate-based BD Rhapsody requires fairly low concentrations of cell suspensions, while a higher concentration is necessary for microdroplet-based systems, like the 10X Genomics [10]. In addition, BD Rhapsody provides quality control of the samples via direct visual inspection of cartridge contents and each microwell [10,90]. Regarding cost efficiency, BD Rhapsody beads can be retained for a longer period, which enables the construction of multiple sequencing libraries from subsample beads. For now, this cannot be achieved by 10X Genomics [10]. Researchers should consider the various scope of applications, cost efficiency and complexity of work flow between these two platforms, when determining which to be applied according to specific purposes.

4.2. Emerging methods based on scRNA-seq

Based on scRNA-seq, several novel single-cell multi-omics technologies have emerged. For example, performing scRNA-seq with oligo-nucleotides labeled antigens or antibodies, have allowed simultaneous detection of gene expression, VDJ, antigen specificity, and cell surface markers [91,92]. These novel immune profiling techniques have been combined to characterize the gene expression and TCR repertoire in breast cancer and paracancerous tissues, blood and lymph nodes. Detailed immune cell maps of multiple immunophenotypes in tumor microenvironment have been drawn via this joint sequencing method, which has deepened our understanding of tumor cell heterogeneity [93].

The newest spatial transcriptomic technology can trace the gene expression information of cells to the original spatial location within the tissue (Fig. 5A). Spatial transcriptome techniques have already been used in cancer related studies. Moncada et al. utilized spatial transcriptome and scRNA-seq to analyze the spatial distribution of immune and non-immune cells in sections of pancreatic cancer, the result of which indicated inflammatory fibroblasts were enriched near tumor cells with high expression of stress response genes [94]. Recently, online analysis platforms for spatial transcription data have been established [95]. With those emerging tools, the visual interpretation of spatial data and annotations for spatially differentially expressed genes and enrichment analysis can be achieved [95]. Besides these advantages, some limitations still need to be addressed. Since spatial transcriptomic technology is built on the chip, the size of measured tissue section is determined by the chip size, and the transcripts diffusion on the chip is inevitable [94]. Additionally, each single measuring spot on the chip actually captures more than a single cell, which will affect the subsequent clustering analysis [7]. Currently, several spatial transcriptomic techniques are developed, including Slide-seq [96], MERFISH (multiplexed, error robust fluorescent in situ hybridization) [97] and seqFISH (sequential fluorescent in situ hybridization) [98]. Those emerging technologies will promote the discovery of medical biology to a new level.

In eukaryotes, DNA is combined with histones to form nucleosomes, which are further folded and compressed to form chromatin. Both DNA replication and transcription require opening the tight chromatin structure to allow regulatory factors to bind to the DNA. This property is called chromatin accessibility. Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) is an integrative epigenomic analysis method that based on in vitro relocation of sequencing adaptors into native chromatin (Fig. 5A) [99]. ATAC-seq could find target genes regulated by transcription factors, or identify regulatory elements required during gene expression. In addition, Chromosome Conformation Capture (3C) technology and its derivatives, such as Hi-C, ChIA-PET, enables high-throughput quantitative sequencing to analyze the three-dimensional structure of the nucleus with superior resolution [100–102].

DNA methylation is an important epigenetic marker (Fig. 5A). It is closely related to gene imprinting, stem cell differentiation, and tumor occurrence / development. Obtaining the single-cell methylome is highly significant in the study of epigenetic spatio-temporal specificity. Currently, detection of DNA methylation at single-cell resolution is possible, although it cannot completely cover all CpG positions [103,104]. Angermueller et al. recently developed a calculation method DeepCpG, which is based on a deep neural network strategy and can fill gaps left by previous methods [105].

Recently, another interesting development called “direct-capture perturb-seq” was reported. This combines clustered regularly interspaced short palindromic repeats (CRISPR) screening with scRNA-seq (Fig. 5A). By using this technique, gene expression changes caused by individual sgRNA and the sgRNA itself can be
measured with single cell precision. This study revealed epistatic interactions between cholesterol biogenesis and DNA repair were revealed [106]. This method combines two important technologies and enables alternative ways to probe the relationship between genes and signal pathways. Therefore, multi-omics analysis methods examine individual cell by various dimensions, and enable comprehensive exploration of cellular characteristics and functions. [107,108].

4.3. Challenges in scRNA-seq

Some challenges still exist for scRNA-seq. Since bacterial mRNA and some viral mRNA do not have a 3' poly-A tail, their mRNA cannot be studied using current scRNA-seq techniques. In addition, doublet identification remains problematic during data analysis [109]. Since doublets have the mixed transcriptome from two cells, it may cause false positive discovery of novel cell subtypes. However, analyzing the doublets may also reveal the authentic cell-to-cell interaction information. Indeed, there is higher percentage of doublets in the blood of patients with tuberculosis and dengue disease [110]. These doublets often consist of T cells and monocytes adhering to each other [110]. Some bioinformatic tools have been created, such as SOLO (a semi-supervised deep neural network model to identify doublets) [111], Scrublet [112] and DoublletFnder [113]. To avoid losing crucial information relevant to the disease, careful consideration should be taken when deciding whether doublets should be excluded from the sequencing analysis.

The results of multi-omics sequencing involve the integration of heterogeneous data from multiple source. For example, when different data from scRNA-seq and ATAC-seq are integrated for analysis, the inconsistency of data characteristics cannot be dealt properly. It is necessary to use algorithms to integrate data from various data source, such as Specific Representation Learning (an analysis strategy that integrates scRNA-seq data sets based on common mutation sources to identify shared populations across data sets and perform downstream comparative analysis) [114,115], MOFA (a computational method that discovers the cooperation between methylation sites and transcriptome) [82], and Manifold Alignment to Characterize Experimental Relationships (MATCHER) (a method that utilizes multiple alignments to infer single-cell multi-omics profiles between transcriptome and epigenetic data achieved on various cells of the same type) [107,116,117]. Among these methods, machine learning is the leading choice with the help of computer sciences [107]. Researchers could use computer programming methods to simplify the complexity between different data sources. By using these programs, these data can be integrated according to the key characteristics. At the same time, the high-speed computing capabilities could capture and predict data that cannot be manually identified. In short, integration of multi-omics could allow researchers to understand how several realms interact. Through high-throughput sequencing of various omics and data integration research, it is possible to comprehensively and systematically understand the interrelationship of multiple substances in the fields of basic research, clinical diagnosis, and drug development. The discovery of valuable immunological information from scRNA-seq results need the collaborative effort of not only comprehensive immunological knowledge, but also intensive data analysis abilities.

Missing values caused by the failure of RNA amplification in cells is a significant problem that exists in scRNA-seq, making it technically impossible to judge whether the gene was missing or not expressed. Imputation is an appropriate method to address the problem [118,119]. For instance, by taking advantage of scRNA-seq, Ben-Moshe et al. exploited a deconvolution algorithm to infer cell-type specific infection responses from bulk RNA-seq data, and this algorithm could provide a predictive power for TB progression [61]. Currently, some tools have been developed to accurately impute dropouts in scRNA-seq data, such as single-cell analysis via expression recovery (SAVER) [118], scImpute [87] and Markov affinity-based graph imputation of cells (MAGIC) [120].

Besides Smart-seq, the sequencing depth of most scRNA-seq technologies is about 1 million reads, this leaves much room for improvement in future [111]. scRNA-seq for lncRNA is currently possible, and sequencing methods for other non-coding RNA are under development [121].

scRNA-seq has greatly improved our understanding about the heterogeneity in various biological process, and has been involved in many breakthroughs throughout immunology, oncology, and developmental biology. With the combination of scRNA-seq and multi-omics analysis, the pathogenic mechanism of various infectious diseases could be quickly and systematically elucidated, significantly propelling vaccine development in the near future.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (81801977), National 13th Five-Year Grand Program on Key Infectious Disease Control and Prevention (2018ZX10301-404-001), the Outstanding Young Training Program of Shanghai Municipal Health Commission (2018YQ54), and Shanghai Sailing Program (18YF1420400).

References

[1] Regev A, Teichmann SA, Lander ES, et al. The human cell atlas. Elife 2017;6.
[2] Clark SJ, Smallwood SA, Lee HJ, Krueger F, Reik W, Kelsey G. Genome-wide base-resolution mapping of DNA methylation in single cells using single-cell bisulfite sequencing (scBS-seq). Nat Protoc 2017;12:534–47.
[3] Corces MR, Granja JM, Shams S, Louie BH, Seoane JA, Zhou W, Silva TC, Groeneveld C, Wong CK, Cho SW, Satpathy AT, Mumbach MR, Hoadley KA, Robertson AG, Sheffield NC, Pelas I, Castro MAA, Berman BP, Staudt LM, Zakowski MF, Laird PW, Curtis C. Cancer Genome Atlas Analysis N, Greenleaf WJ, Chang HY. The chromatin accessibility landscape of primary human cancers. Science 2018;362.
[4] Vanhaeren T, Divina F, Garcia-Torres M, Gomez-Vela F, Vanhoof W, Martinez-Garcia PM. A comparative study of supervised machine learning algorithms for the prediction of long-range chromatin interactions. Genes (Basel) 2020;11.
[5] Cheung VS, Vallania F, Warsinske HC, Donato M, Schaffert S, Chang SE, et al. Single-cell chromatin modification profiling reveals increased epigenetic variations with aging. Cell 2018;173(1385-97):e14.
[6] Vermeulen M, Eberl HC, Matarese F, Marks H, Denissenov S, Butler F, et al. Quantitative interaction proteomics and genome-wide profiling of epigenetic histone marks and their readers. Cell 2010;142:967–80.
[7] Chen J, Suo S, Tam PM, Han J, Peng C, Jing N. Spatial transcriptomic analysis of cryosectioned tissue samples with Geo-seq. Nat Protoc 2017;12:566–80.
[8] Zheng GX, Terry JM, Belgrader P, Rybski P, Bent ZW, Wilson R, et al. Massively parallel digital transcriptional profiling of single cells. Nat Commun 2017;8:14049.
[9] Fan HC, Fu GK, Fodor SP. Expression profiling. Combinatorial labeling of single cells for gene expression cytometry. Science 2015;347:1258367.
[10] Shum EY, Walczak EM, Chang C, Christina FH. Quantification of mRNA transcripts and proteins using the BD rhapsody single-cell analysis system. Adv Exp Med Biol 2019;1129:63–79.
[11] Ziegenhain C, Vieh B, Parikh S, Reinus B, Guillaume-Adkins A, Smets M, et al. Comparative analysis of single-cell RNA sequencing methods. Mol Cell 2017;65:631–43:e4.
[12] Svensson V, Natarajan KN, Ly LH, Miragaia RJ, Labalette C, Macaulay IC, et al. Power analysis of single-cell RNA-sequencing experiments. Nat Methods 2017;14:381–7.
[13] Tang F, Barbacicou C, Wang Y, Nordman E, Lee C, Xu N, et al. mRNA-Seq whole-transcriptome analysis of a single cell. Nat Methods 2009;6:377–82.
[14] Park E, Patel S, Wang Q, Andhey P, Zaitsev K, Porter S, et al. Toxoplasma gondii infection drives conversion of NK cells into ILC1-like cells. Elife 2019;8.
[15] Abbas A, Yu Manh TP, Valente M, Collinett N, Attal N, Dong C, et al. The activation trajectory of NK and dendritic cells in vivo during a viral infection. Nat Immunol 2020;21:983–97.
[16] Zhang L, Yu X, Zheng L, Zhang Y, Li Y, Fan Q, et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature 2018;564:268–72.
[17] Wilk AJ, Rustagi A, Zhao NQ, Roque J, Martinez-Colon GJ, McKeechnie JL, et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med 2020;26:1070–6.
[18] Zhang JY, Wang XM, Xing X, Xu Z, Zhang C, Song JW, et al. Single-cell landscape of immunological responses in patients with COVID-19. Nat Med 2020;26:1110–7.
[19] He J, Cai S, Feng H, Cai B, Lin M, Bai Y, et al. Single-cell analysis reveals bronchoalveolar epithelial dysfunction in COVID-19 patients. Protein Cell 2020;11:680–7.
[20] Horns F, Dekker CL, Quake SR. Memory B cell activation, broad anti-influenza antibodies, and bystander activation revealed by single-cell transcriptomics. Cell Rep 2020;30:905–13.
[21] Wen W, Su W, Tang H, Lei W, Zhang X, Zheng Y, et al. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. Cell Discov 2020;6:31.
[22] Shrestha Y, Cohen M, Peshes-Yaloz V, Valadarsky L, Cohn D, David E, et al. Dissection of influenza infection in vivo by single-cell RNA sequencing. Cell Syst 2018;6:579–91.
[23] Zhang J, Ye C, Shi W, Yao L, Lai H, Han S, et al. A mass cytometry signature for SARS-CoV-2 entry in human ACE2-expressing cells. Cell 2020;181:271–80.
[24] Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 2020;181:1904–9.
[25] Qi F, Qian S, Zhang S, Zhang Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem Biophys Res Commun 2020;526:135–40.
[26] Zhang H, Rostami MR, Leopold PL, Mezey JG, O’Beirne SL, Strulovici-Barel Y, et al. Expression of SARS-CoV-2 ACE2 receptor in the human airway epithelium. Am J Respir Crit Care Med 2020;212:219–29.
[27] Hoffmann M, Kleine-Weber H, Schroder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;180:271–80.
[28] Ziegler CGK, Allon SJ, Nyquist SK, Mbanok BM, Miao VN, Tzouanas CN, et al. Benchmarking single-cell RNA-sequencing protocols for cell atlas construction. Nat Methods 2013;10:135–68.
[29] Zhang J, Zhan Y, Deng Y, Bao L, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell 2020.
[30] Bost P, Giladi A, Liu Y, Bendjelal Y, Xu G, David E, Blecher-Gonen R, Cohen M, Medaglia C, Li H, Deczkowska A, Zhang S, Schwikowski B, Zhang Z, Amit I. Host-viral infection maps reveal signatures of severe COVID-19 patients. Cell. 2020;181(1016–20):e19.
[31] Calis JJ, Rosenberg BR. Characterizing immune repertoires by high throughput sequencing: strategies and applications. Trends Immunol 2014;35:581–90.
[32] Boswell Ben-Moshe N, Hen-Avi S, Levinit N, Yehezkel D, Oosting M, Joosten LAB, et al. Predicting bacterial infection outcomes using single cell-RNA sequencing analysis of human immune cells. Nat Commun 2019;10:3266.
[33] Bost P, Giladi A, Liu Y, Bendjelal Y, Xu G, David E, Blecher-Gonen R, Cohen M, Medaglia C, Li H, Deczkowska A, Zhang S, Schwikowski B, Zhang Z, Amit I. Predicting bacterial infection outcomes using single cell-RNA sequencing: strategies and applications. Trends Immunol 2014;35:581–90.
[34] Bost P, Giladi A, Liu Y, Bendjelal Y, Xu G, David E, Blecher-Gonen R, Cohen M, Medaglia C, Li H, Deczkowska A, Zhang S, Schwikowski B, Zhang Z, Amit I. Host-viral infection maps reveal signatures of severe COVID-19 patients. Cell. 2020;181(1016–20):e19.
[35] Calis JJ, Rosenberg BR. Characterizing immune repertoires by high throughput sequencing: strategies and applications. Trends Immunol 2014;35:581–90.
[75] Roy Chowdhury R, Vallania F, Yang Q, Lopez Angel CJ, Darboe F, Penn-Nicholson A, et al. A multi-cohort study of the immune factors associated with M. tuberculosis infection outcomes. Nature 2018;560:644–8.
[76] Plass M, Solana J, Wolf PA, Ayoub S, Missio A, Glazar P, et al. Cell type atlas and lineage tree of a whole complex animal by single-cell transcriptomics. Science 2018;360.
[77] Fischer CF, Wurtzel O, de Hoog T, Kravarik KM, Reinders PW, Cell type transcriptome atlas for the planarian Schmidtea mediterranea. Science 2018;360.
[78] Hovestadt V, Smith KS, Bihannic L, Filbin MG, Shaw ML, Baumgartner A, et al. Resolving medulloblastoma cellular architecture by single-cell genomics. Nature 2019;572:74–9.
[79] Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014;344:1396–401.
[80] Luecken MD, Theis FJ. Current best practices in single-cell RNA-seq analysis: a tutorial. Mol Syst Biol 2019;15:e8746.
[81] Welch JD, Kozareva V, Ferreira A, Vanderburg C, Martin C, Macosko EZ. Single-cell multi-omic integration compares and contrasts features of brain cell identity. Cell 2019;177:1873–87; e17.
[82] Angelaruet R, Velten B, Arndt D, Dietrich S, Zenz T, Marioni JC, et al. Multi-Omics Factor Analysis—a framework for unsupervised integration of multi-omics data sets. Mol Syst Biol 2018;14:e8124.
[83] Franzén O, Bjorkegren JLM. alona: a web server for single-cell RNA-seq. Bioinformatics 2020;36:3910–2.
[84] Alavi A, Ruffalo M, Parvazandeh A, Huang Z, Bar-Joseph Z. A web server for comparative analysis of single-cell RNA-seq data. Nat Commun 2018;9:4768.
[85] Peng T, Zhu Q, Yin Y, Pan T. KSCRALE: single-cell RNA-seq imputation constrained by bulk RNA-seq data. Genome Biol 2019;20:88.
[86] Mongia A, Sengupta D, Majumdar A, Mccinple: matrix completion based imputation for single cell RNA-seq data. Front Genet 2019;10:9.
[87] Li WW, Li J. An accurate and robust imputation method scmpuente for single-cell RNA-seq data. Nat Commun 2018;9:997.
[88] Nazarov PV, Muller A, Kaoma T, Nicot N, Maximo C, Birembaut P, et al. RNA sequencing and transcriptome arrays analyses show opposing results for alternative splicing in patient derived samples. BMC Genom 2017;18:443.
[89] Stahl PL, Salmen F, Vickovic S, Lundmark A, Navarro JF, Magnusson J, et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science 2016;353:78–82.
[90] Birey F, Andersen J, Makinson CD, Islam S, Wei W, Huber N, et al. Assembly of functionally integrated human forebrain spheroids. Nature 2017;545:54–9.
[91] Peterson VM, Zhang KK, Kumar N, Wong J, Li L, Wilson DC, et al. Multiplexed quantification of proteins and transcripts in single cells. Nat Biotechnol 2017;35:936–9.
[92] Stoeckius M, Halemeister C, Stephenson W, Houck-Loomis B, Chastopadhyay PK, Sverdlow H, et al. Simultaneous epitope and transcriptome measurement in single cells. Nat Methods 2017;14:865–6.
[93] Atzaz E, Carr AJ, Pilates G, Cornish AE, Konopacki C, Prabhakaran S, et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 2018;174:1291–308; e36.
[94] Moncada R, Barkley D, Wagner F, Chiodin M, Devlin JC, Baron M, et al. Integrating microarray-based spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinomas. Nat Biotechnol 2020;38:333–42.
[95] Fan Z, Chen R, Chen X. SpatialDB: a database for spatially resolved transcriptomes. Nucleic Acids Res 2020;48:D233–7.
[96] Rodrigues SC, Stichels RK, Goes A, Martin CA, Murray E, Vanderburg CR, et al. Slide-seq: a scalable technology for measuring genome-wide expression at high spatial resolution. Science 2019;363:1463–7.
[97] Chen KH, Boettiger AN, Moffitt JR, Wang S, Zhuang X. RNA imaging. Spatially resolved, highly multiplexed RNA profiling in single cells. Science 2015;348:aa9090.
[98] Shah S, Lubeck E, Zhou W, Cai L. In situ transcription profiling of single cells reveals spatial organization of cells in the mouse hippocampus. Neuron 2016;92:342–57.
[99] Buenrostro JD, Giresi PG, Zaba LC, Chang HY, Greenleaf WJ. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat Methods 2013;10:1213–8.
[100] Tolvais B, Palstra R, Splinter E, Grosveld F, de Laat W. Looping and interaction between hypersensitive sites in the active beta-globin locus. Mol Cell 2002;10:1453–65.
[101] Li G, Liu Y, Zhang Y, Kubo N, Yu M, Fang R, et al. Joint profiling of DNA methylation and chromatin architecture in single cells. Nat Methods 2019;16:991–3.
[102] Fullwood MJ, Han Y, Wei CI, Ruan X, Ruan Y. Chromatin interaction analysis using paired-end Tag sequencing. Curr Protoc Mol Biol Chapter 21; 2010;21:15:1–25.
[103] Smallwood SA, Lee HJ, Angermueller C, Krueger F, Saadeh H, Peat J, et al. Single-cell genome-wide bisulfite sequencing for assessing epigenetic heterogeneity. Nat Methods 2014;11:817–20.
[104] Farlik M, Sheffield NC, Nuzzo A, Datlinger P, Schongegger A, Klughammer J, et al. Single-cell DNA methylation sequencing and biomimetic inference of epigenomic cell-state dynamics. Cell Rep 2015;10:1386–97.
[105] Angermueller C, Lee HJ, Reik W, Stegle O. DeepCGP: accurate prediction of single-cell DNA methylation states using deep learning. Genom Biol 2017;18:67.
[106] Repliee JM, Norman TM, Xu A, Hussmann JA, Chen J, Cogan JZ, et al. Combinatorial single-cell CRISPR screens by direct guide RNA capture and targeted sequencing. Nat Biotechnol 2020.
[107] Ma A, McDermad A, Xu J, Chang Y, Ma Q, Integrative Methods and Practical Challenges for Single-Cell Multi-omics. Trends Biotechnol 2020;38:1007–22.
[108] Method of the Year 2019: Single-cell multimodal omics. Nat Methods 2012;7:1.
[109] Hedlund E, Deng Q. Single-cell RNA sequencing: technical advancements and biological applications. Mol Aspects Med 2018;59:36–46.
[110] Burel JP, Pomaznoy M, Lindestam Arlehamn CS, Weiskopf D, da Silva AR, Jung Y, et al. Circulating T cell-monocyte complexes are markers of immune perturbations. Elife 2019;8.
[111] Bernstein NJ, Fong NL, Lam L, Roy MA, Hendrickson DG, Kelrey DR. Solo: doublet identification in single-cell RNA-Seq via semi-supervised deep learning. Cell Syst 2020;11:95–101; e5.
[112] Wolock SL, Lopez R, Klein AM. Scrublet: computational identification of cell doublets in single-cell transcriptomic data. Cell Syst 2019;9:821–91; e9.
[113] McGinnis CS, Murrow LM, Gartner ZJ. DoubletFinder: doublet detection in single-cell RNA-seq data using artificial nearest neighbors. Cell Syst 2019;8:329–37; e4.
[114] Li X, Chen W, Chen Y, Zhang X, Gu J, Zhang MQ. Network embedding-based representation learning for single-cell RNA-seq data. Nucleic Acids Res 2017;45:e166.
[115] Butler A, Hoffman P, Smibert P, Papalexis E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol 2018;36:411–20.
[116] Colomé-Tatché M, Theis FJ. Statistical single cell multi-omics integration. Curr Opin Biol 2018;7:54–9.
[117] Welch JD, Hwang S, Alonsom AW, Harro M, Himmelfarb JL. MATCHER: manifold alignment reveals correspondence between single cell transcriptome and epigenome dynamics. Genom Biol 2017;18:138.
[118] Huang M, Wang J, Torre E, Dueck H, Shaffer S, Bonasio R, et al. SAVER: gene expression recovery for single-cell RNA sequencing. Nat Methods 2018;15:539–42.
[119] Ouyang M, Welsh WJ. Georgopoulos P, Gaussian mixture clustering and imputation of microarray data. Bioinformatics 2004;20:917–23.
[120] van Dijk D, Sharma R, Nainys J, Yim K, Kathail P, Carr AJ, et al. Recovering gene interactions from single-cell data using data diffusion. Cell 2018;174:716–29; e27.
[121] Yan L, Yang M, Guo H, Yang L, Wu J, Li R, et al. Single-cell RNA-Seq profiling of human preimplantation embryos and embryonic stem cells. Nat Struct Mol Biol 2013;20:1131–9.